Table 1.
A brief overview of anti – CD 19 mAbs
| Antibody | Internal name | Antigen | Company | Phase | Condition | Antibody type |
|---|---|---|---|---|---|---|
| Blinatumomab | AMG103 | CD19,CD3 | Amgen | Approved 1 |
ALL NHL |
× |
| Coltuximabravtansine | SAR3419, huB4-DM4 | CD19 | ImmunoGen Inc. Sanofi-aventis | 2 1 |
ALL, NHL |
Humanized mouse antibody drug conjugate/IgG1 |
| MOR208 | XmAb 5574 | CD19 | Morphosys AG, Xencor Inc. | 2 1 |
ALL, NHL CLL |
Humanized mouse antibody |
| MEDI-551 | MEDI-551 | CD19 | Medimmune | 2 | B-cell malignancies, CL L, Multiple Myeloma, Scleroderma | Humanized mouse antibody |
| Denintuzumabmafodotin | SGN-19A, SGN-CD19A, BU12 | CD19 | Seattle Genetics | 1 | NHL | Humanized undefined source antibody drug conjugate/IgG1 |
| Merck patent anti-CD19 | B4, DI-B4 | CD19 | Merck Serono | 1 | B-cell malignancies | Humanized mouse antibody |
| Taplitumomabpaptox | Taplitumomabpaptox | CD19 | National Cancer Institute | 1 | B-cell malignancies | Mouse antibody drug conjugate/IgG1 |
| XmAb 5871 | XmAb 5871 | CD19 | Amgen, Xencor Inc. | 1 | Autoimmune Diseases | Humanized undefined source antibody |
| MDX-1342 | MDX-1342 | CD19 | Medarex | 1 | CLL,Rheumatoid Arthritis | Human-from transgenic mouse antibody |
| AFM11 | AFM11 | CD19, CD3 | Affimed | 1 | NHL | Human bispecific antibody |
CD: cluster of differentiation; ALL: acute lymphoblastic leukemia; BiTE: bispecifc T cell engager; CLL: chronic lymphocytic leukemia; NHL: non-Hodgkin lymphoma.